Download PDF
Der Nuklearmediziner 2009; 32(2): 131-134
DOI: 10.1055/s-0028-1112124
Nicht-FDG-PET

© Georg Thieme Verlag KG Stuttgart · New York

18F-DOPA-PET bei neuroendokrinen Tumoren (NET)

18F-DOPA-PET in Neuroendocrine Tumours (NET)B. Beuthien-Baumann 1
  • 1Klinik und Poliklinik für Nuklearmedizin, Medizinische Fakultät, Universitätsklinikum Carl Gustav Carus, TU Dresden, PET-Zentrum Dresden-Rossendorf
Further Information

Publication History

Publication Date:
22 June 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Der Nachweis von NET mittels planarer Szintigrafie oder Single-Photonen-Emissions-Tomografie (SPECT) ist gerade bei kleinen Befunden trotz spezifischer Radiopharmaka wie 111In-Octreotid oder 123I-MIBG durch die begrenzte Auflösung der Gammakamera limitiert. Die Positronenemissionstomografie (PET) hat gegenüber der konventionellen Bildgebung den Vorteil der höheren Ortsauflösung, die bei onkologischen Fragestellung am häufigsten eingesetzte 18F-Fluordesoxyglukose ist jedoch eher zum Nachweis von entdifferenzierten NET geeignet. Für den Einsatz der 18F-DOPA-PET bei neuroendokrinen Tumoren liegen wenige, aber in Hinblick auf die Sensitivität des Tumornachweises, viel versprechende Studien vor. Der Stellenwert von 18F-DOPA im Vergleich zu den 68Ga-markierten Somatostatinrezeptorliganden wird in Studien zu klären sein.

Abstract

Despite highly specific radiopharmaceuticals like 111In-Octreotide or 123I-MIBG, detection of small neuroendocrine tumours (NET) can be hampered due to the limited resolution of planar scintigraphy and SPECT. 18F-FDG, the workhorse in oncological high resolution PET diagnostic, is mainly positive in undifferentiated NETs. For 18F-DOPA, a limited number of studies are published, demonstrating favourable results in tumour detection of NETs. The role of 18F-DOPA in comparison to 68Ga-labeled somatostatin-receptor ligands will have to be defined in future studies.

Schlüsselwörter

18F-DOPA - PET - Neuroendokrine Tumore

Key words

18F-DOPA - PET - neuroendocrine tumours

Literatur

  • 1 Adams S, Baum R, Rink T. et al . Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.  Eur J Nucl Med. 1998;  25 79-83
    PubMedGoogle Scholar
  • 2 Ambrosini V, Tomassetti P, Castellucci P. et al . Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.  Eur J Nucl Med Mol Imaging. 2008;  35 1431-1438
    CrossrefPubMedGoogle Scholar
  • 3 Beuthien-Baumann B, Strumpf A, Zessin J. et al . Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.  Eur J Nucl Med Mol Imaging. 2007;  34 1604-1609
    CrossrefPubMedGoogle Scholar
  • 4 Böcker W, Denk H, Heitz PU. Pathologie. München: Urban & Fischer 2001
  • 5 Brown WD, Oakes TR, DeJesus OT. et al . Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment.  J Nucl Med. 1998;  39 1884-1891
    PubMedGoogle Scholar
  • 6 Diehl M, Risse JH, Brandt-Mainz K. et al . Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.  Eur J Nucl Med. 2001;  28 1671-1676
    CrossrefPubMedGoogle Scholar
  • 7 Gilbert JA, Bates LA, Ames MM. Elevated aromatic-L-amino acid decarboxylase in human carcinoid tumors.  Biochem Pharmacol. 1995;  50 845-850
    CrossrefPubMedGoogle Scholar
  • 8 Hardy OT, Hernandez-Pampaloni M, Saffer JR. et al . Accuracy of [18F] fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.  J Clin Endocrinol Metab. 2007;  92 4706-4711
    CrossrefPubMedGoogle Scholar
  • 9 Herholz K, Herscovitch P, Heiss W. Movement Disorders. In: NeuroPET. Berlin Heidelberg: Springer;. 2004 p: 32-63
    Google Scholar
  • 10 Hoegerle S, Altehoefer C, Ghanem N. et al . 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.  Eur J Nucl Med. 2001;  28 64-71
    CrossrefPubMedGoogle Scholar
  • 11 Hoegerle S, Altehoefer C, Ghanem N. et al . Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.  Radiology. 2001;  220 373-380
    PubMedGoogle Scholar
  • 12 Hoegerle S, Ghanem N, Altehoefer C. et al . 18F-DOPA positron emission tomography for the detection of glomus tumours.  Eur J Nucl Med Mol Imaging. 2003;  30 689-694
    CrossrefPubMedGoogle Scholar
  • 13 Hoegerle S, Nitzsche E, Altehoefer C. et al . Pheochromocytomas: detection with 18F DOPA whole body PET-initial results.  Radiology. 2002;  222 507-512
    CrossrefPubMedGoogle Scholar
  • 14 Kauhanen S, Seppanen M, Minn H. et al . Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients.  J Clin Endocrinol Metab. 2007;  92 1237-1244
    CrossrefPubMedGoogle Scholar
  • 15 Koopmans KP, Brouwers AH, Hooge MN De. et al . Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid.  J Nucl Med. 2005;  46 1240-1243
    PubMedGoogle Scholar
  • 16 Koopmans KP, Groot JW de, Plukker JT. et al . 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.  J Nucl Med. 2008;  49 524-531
    CrossrefPubMedGoogle Scholar
  • 17 Koopmans KP, Vries EG de, Kema IP. et al . Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.  Lancet Oncol. 2006;  7 728-734
    CrossrefPubMedGoogle Scholar
  • 18 Koopmans KP, Neels OC, Kema IP. et al . Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.  J Clin Oncol. 2008;  26 1489-1495
    CrossrefPubMedGoogle Scholar
  • 19 Kwekkeboom D, Krenning E. Somatostatin receptor imaging.  Semin Nucl Med. 2002;  32 84-91
    CrossrefPubMedGoogle Scholar
  • 20 Mackenzie IS, Gurnell M, Balan KK. et al . The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma.  Eur J Endocrinol. 2007;  157 533-537
    CrossrefPubMedGoogle Scholar
  • 21 Mohnike K, Blankenstein O, Minn H. et al . 18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism.  Horm Res. 2008;  70 65-72
    CrossrefPubMedGoogle Scholar
  • 22 Montravers F, Grahek D, Kerrou K. et al . Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?.  J Nucl Med. 2006;  47 1455-1462
    PubMedGoogle Scholar
  • 23 Nataf V, Balard M, Beco V de. et al . Safety of 18F-DOPA injection for PET of carcinoid tumor.  J Nucl Med. 2006;  47 1732 , ; author reply 1732.
    PubMedGoogle Scholar
  • 24 Orlefors H, Sundin A, Lu L. et al . Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography.  Eur J Nucl Med Mol Imaging. 2006;  33 60-65
    CrossrefPubMedGoogle Scholar
  • 25 Pearse AG. The APUD cell concept and its implications in pathology.  Pathol Annu. 1974;  9 27-41
    PubMedGoogle Scholar
  • 26 Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors.  Semin Nucl Med. 2006;  36 228-247
    CrossrefPubMedGoogle Scholar
  • 27 Schipper J, Boedeker CC, Maier W. et al . Paragangliomas in the head-/neck region.  I: Classification and diagnosis]. HNO. 2004;  52 569-574 , ; quiz 575.
    PubMedGoogle Scholar
  • 28 Timmers HJ, Hadi M, Carrasquillo JA. et al . The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.  J Nucl Med. 2007;  48 1599-1606
    CrossrefPubMedGoogle Scholar
  • 29 Harst E van der, de Herder WW, Bruining HA. et al . [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas.  J Clin Endocrinol Metab. 2001;  86 685-693
    CrossrefPubMedGoogle Scholar

Korrespondenzadresse

Dr. B. Beuthien-Baumann

Klinik und Poliklinik für Nuklearmedizin

Universitätsklinikum Carl Gustav Carus

Technische Universität Dresden

Fetscherstr. 74

01307 Dresden

Phone: +49/351/260 27

Fax: +49/351/260 36 49

Email: b.beuthien@fz-rossendorf.de